Emilie Stern
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emilie Stern has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Pierre Alexis Geoffroy
Inserm U1141, Université de Paris, NeuroDiderot Paris France
11 shared publications Michel Lejoyeux
Centre ChronoS, GHU Paris - Psychiatry & Neurosciences, 1 rue Cabanis, 75014 Paris, France; Université Paris Cité, NeuroDiderot, Inserm, FHU I2-D2, F-75019 Paris, France; Département de psychiatrie et d'addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hopital Bichat - Claude Bernard, F-75018 Paris, France
8 shared publicationsJulia Maruani
Centre ChronoS, 75G22, GHU Paris - Psychiatry & Neurosciences, DMU Neurosciences, Paris, France; Département de psychiatrie et d'addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, hôpital Bichat-Claude-Bernard, 75018 Paris, France; Université Paris Cité, NeuroDiderot, Inserm, UMR1141, équipe SleepCmd, Paris, France
6 shared publications- Julia Maruani
Département de psychiatrie et d'addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hôpital Bichat–Claude Bernard , Paris F-75018
5 shared publications Emmanuelle Clerici
Centre ChronoS GHU Paris ‐ Psychiatry & Neurosciences Paris France
4 shared publications- Stéphane Mouchabac
Department of Psychiatry, Saint-Antoine Hospital, DMU neurosciences, AP-HP, Sorbonne université, Paris, France; ICRIN Psychiatry, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne université, Paris, France
4 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Online Recruitment for Psychometric Research and Development of the Comprehensive Report of Insomnia Symptoms (CRIS) a digital PROM : Sequential Psychometric Validation Study (Preprint)
BACKGROUND PROMs are important in insomnia, where diagnosis and treatment outcomes rely on patients’ subjective experience of sleep difficulties and daytime consequences. The 10-item Comprehensive Report of Insomnia Symptoms (CRIS) was developed as a brief digital PROM to capture these dimensions. OBJECTIVE To evaluate the structural and external validity, responsiveness, and score interpretation of the CRIS and the feasibility of a sequential psychometric validation strategy based on open online recruitment. METHODS The CRIS was developed through a literature review, multidisciplinary expert consultation, and two rounds of cognitive interviews. Structural validation used a sequential two-wave design, with confirmatory factor analysis in an initial online sample (N=568), followed by item revision and independent validation of the modified model (N=457), including measurement invariance across sex and age. External validation against the ISI was conducted in a separate clinical sample (N=115 at baseline; N=61 at Week 4), assessing convergent and known-groups validity, responsiveness, and exploratory ISI-anchored score ranges. RESULTS In the first wave, Q2 and Q8 showed the weakest factor loadings and helped guide revision of the scale. In Wave 2, standardized loadings ranged from 0.436 to 0.834 and the two factors were moderately correlated (r=0.525). Fit of the prespecified model was mixed (CFI=0.924, TLI=0.900, SRMR=0.0588, RMSEA=0.0943), whereas a post hoc sensitivity model allowing residual covariance between Q3 and Q5 showed improved fit (CFI=0.964, TLI=0.951, SRMR=0.0462, RMSEA=0.0659). Metric invariance across sex and age groups was supported in sensitivity analyses. CRIS scores correlated with ISI scores at baseline (r=−0.34), with a stronger association at Week 4 (r=−0.66). CRIS scores varied systematically across predefined ISI strata, supporting convergent and known-groups validity. Among participants with longitudinal data, changes in CRIS and ISI scores were correlated. Exploratory ROC analyses identified four descriptive CRIS score ranges (≥67, 45–66, 17–44, and ≤16), with 66.5% exact agreement and 98.9% agreement within the same or an adjacent ISI category. An increase of approximately 24 points in the CRIS score showed 77% sensitivity and 77% specificity for correspondence with an improvement of at least 7 points on the ISI (AUC=0.79). CONCLUSIONS The CRIS is a brief digital PROM with a coherent two-factor structure, evidence of convergent validity, and evidence of responsiveness to patient-reported change. Sequential evaluation in two independently recruited online samples, together with metric invariance across sex and age, supports the feasibility of structured psychometric validation using this type of recruitment. Its brief visual-analogue format and suitability for repeated administration make the CRIS particularly relevant to digital clinical settings, including longitudinal monitoring during CBT-I and digital CBT-I.
- 22 October 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessOnline Recruitment for Psychometric Research and Development of the Comprehensive Report of Insomnia Symptoms (CRIS) a digital PROM : Sequential Psychometric Validation Study (Preprint)
BACKGROUND PROMs are important in insomnia, where diagnosis and treatment outcomes rely on patients’ subjective experience of sleep difficulties and daytime consequences. The 10-item Comprehensive Report of Insomnia Symptoms (CRIS) was developed as a brief digital PROM to capture these dimensions. OBJECTIVE To evaluate the structural and external validity, responsiveness, and score interpretation of the CRIS and the feasibility of a sequential psychometric validation strategy based on open online recruitment. METHODS The CRIS was developed through a literature review, multidisciplinary expert consultation, and two rounds of cognitive interviews. Structural validation used a sequential two-wave design, with confirmatory factor analysis in an initial online sample (N=568), followed by item revision and independent validation of the modified model (N=457), including measurement invariance across sex and age. External validation against the ISI was conducted in a separate clinical sample (N=115 at baseline; N=61 at Week 4), assessing convergent and known-groups validity, responsiveness, and exploratory ISI-anchored score ranges. RESULTS In the first wave, Q2 and Q8 showed the weakest factor loadings and helped guide revision of the scale. In Wave 2, standardized loadings ranged from 0.436 to 0.834 and the two factors were moderately correlated (r=0.525). Fit of the prespecified model was mixed (CFI=0.924, TLI=0.900, SRMR=0.0588, RMSEA=0.0943), whereas a post hoc sensitivity model allowing residual covariance between Q3 and Q5 showed improved fit (CFI=0.964, TLI=0.951, SRMR=0.0462, RMSEA=0.0659). Metric invariance across sex and age groups was supported in sensitivity analyses. CRIS scores correlated with ISI scores at baseline (r=−0.34), with a stronger association at Week 4 (r=−0.66). CRIS scores varied systematically across predefined ISI strata, supporting convergent and known-groups validity. Among participants with longitudinal data, changes in CRIS and ISI scores were correlated. Exploratory ROC analyses identified four descriptive CRIS score ranges (≥67, 45–66, 17–44, and ≤16), with 66.5% exact agreement and 98.9% agreement within the same or an adjacent ISI category. An increase of approximately 24 points in the CRIS score showed 77% sensitivity and 77% specificity for correspondence with an improvement of at least 7 points on the ISI (AUC=0.79). CONCLUSIONS The CRIS is a brief digital PROM with a coherent two-factor structure, evidence of convergent validity, and evidence of responsiveness to patient-reported change. Sequential evaluation in two independently recruited online samples, together with metric invariance across sex and age, supports the feasibility of structured psychometric validation using this type of recruitment. Its brief visual-analogue format and suitability for repeated administration make the CRIS particularly relevant to digital clinical settings, including longitudinal monitoring during CBT-I and digital CBT-I.
- Open Access
- 10 April 2026
- Published by Elsevier in L'Encéphale
- Vol. 52 (3) , S81-S93
Treatment of insomnia disorder in psychiatry: A practical guide for CBT-I based intervention
- 10 April 2026
- Published by Elsevier in L'Encéphale
- Vol. 52 (3) , S81-S93
Open AccessTreatment of insomnia disorder in psychiatry: A practical guide for CBT-I based intervention
- 28 February 2026
- Published by Elsevier in Psychiatry Research
- Vol. 360, 117058
Predictors of cognitive-behavioral therapy for insomnia (CBT-I) outcomes in individuals with psychiatric disorders: A retrospective observational cohort study
- 28 February 2026
- Published by Elsevier in Psychiatry Research
- Vol. 360, 117058
Predictors of cognitive-behavioral therapy for insomnia (CBT-I) outcomes in individuals with psychiatric disorders: A retrospective observational cohort study
- 4 July 2025
- Published by Elsevier in L'Encéphale
- Vol. 52 (2) , 114-124
Validation of the French version of the Insomnia Severity Index in a population with psychiatric disorders and sleep complaints
- 4 July 2025
- Published by Elsevier in L'Encéphale
- Vol. 52 (2) , 114-124
Validation of the French version of the Insomnia Severity Index in a population with psychiatric disorders and sleep complaints
- Open Access
- 27 May 2025
- Published by JMIR Publications Inc. in JMIR Human Factors
- Vol. 12 (1) , e70193
Innovative Digital Cognitive Behavioral Treatment for Insomnia Disorder in Adults (dCBT-i): Framework Development
Background: Chronic insomnia, or insomnia disorder, is a major health issue with a prevalence of up to 15%. The recommended first-line treatment is cognitive behavioral therapy for insomnia (CBT-i), which, unfortunately, remains insufficiently accessible. Digitalization has the potential to reduce health care access inequalities by offering more flexible and accessible care options. Digital CBT-i (dCBT-i) has been shown to be as effective as in-person CBT-i, highlighting its potential for broader implementation. Objective: This study aimed to develop an evidence-based dCBT-i program grounded in theoretical and clinical knowledge, designed for efficient integration into health care systems, and to establish it as the first prescribed digital treatment in France. Methods: The program was constructed based on validated CBT-i theory and practice, incorporating the latest scientific data on CBT for insomnia. It was designed as a robust multicomponent therapy, integrating an initial standardized assessment and daily intelligent adaptation to enable digital phenotyping and provide personalized treatment. Results: We developed an innovative digital solution that combines scientific rigor with practical application. The program includes a standardized initial evaluation and dynamic personalization through intelligent algorithms. These features allow for the adaptation of therapy based on patient progress and needs, ensuring individualized care. Conclusions: The development of this dCBT-i program represents a significant milestone in digital health care, offering a scalable solution to the accessibility challenges of traditional CBT-i. Future steps involve conducting clinical studies to further evaluate its effectiveness and optimize its implementation within health care systems.
- 27 May 2025
- Published by JMIR Publications Inc. in JMIR Human Factors
- Vol. 12 (1) , e70193
Open AccessInnovative Digital Cognitive Behavioral Treatment for Insomnia Disorder in Adults (dCBT-i): Framework Development
Background: Chronic insomnia, or insomnia disorder, is a major health issue with a prevalence of up to 15%. The recommended first-line treatment is cognitive behavioral therapy for insomnia (CBT-i), which, unfortunately, remains insufficiently accessible. Digitalization has the potential to reduce health care access inequalities by offering more flexible and accessible care options. Digital CBT-i (dCBT-i) has been shown to be as effective as in-person CBT-i, highlighting its potential for broader implementation. Objective: This study aimed to develop an evidence-based dCBT-i program grounded in theoretical and clinical knowledge, designed for efficient integration into health care systems, and to establish it as the first prescribed digital treatment in France. Methods: The program was constructed based on validated CBT-i theory and practice, incorporating the latest scientific data on CBT for insomnia. It was designed as a robust multicomponent therapy, integrating an initial standardized assessment and daily intelligent adaptation to enable digital phenotyping and provide personalized treatment. Results: We developed an innovative digital solution that combines scientific rigor with practical application. The program includes a standardized initial evaluation and dynamic personalization through intelligent algorithms. These features allow for the adaptation of therapy based on patient progress and needs, ensuring individualized care. Conclusions: The development of this dCBT-i program represents a significant milestone in digital health care, offering a scalable solution to the accessibility challenges of traditional CBT-i. Future steps involve conducting clinical studies to further evaluate its effectiveness and optimize its implementation within health care systems.
- Open Access
- 28 February 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (3)
Nightmares Fluctuate Across the Menstrual Cycle and May be More Pronounced in Women With Premenstrual Syndrome
Introduction: Premenstrual syndrome (PMS) affects nearly half of women worldwide and is associated with sleep disturbances, though the specific relationship between PMS and nightmares remains underexplored. Clinical observations suggest a potential link, leading this study to investigate whether women with PMS experience more frequent or intense nightmares compared to those without PMS.Methods: We conducted a prospective case series of seven women experiencing nightmares, all of whom participated in weekly imagery rehearsal therapy (IRT) over 1‐month. Each participant completed the daily record of severity of problems (DRSP) to assess PMS symptoms and kept daily dream diaries throughout one menstrual cycle, tracking nightmare frequency, intensity, and emotional valence. The nightmare severity index (NSI) was administered at the beginning and end of the study. Descriptive analysis was used for the dream metrics, and the Wilcoxon signed‐rank test was employed to assess changes in NSI scores.Results: Women with PMS exhibited an increase in nightmare frequency during the premenstrual phase, but no formal statistical comparisons were made between PMS and non‐PMS groups regarding dream frequency or intensity. A significant reduction in NSI scores (p = 0.03) was observed across the entire sample, though this effect was not significant in the PMS subgroup.Conclusions: This case series is the first, to our knowledge, to provide detailed longitudinal data indicating that nightmare frequency may fluctuate across the menstrual cycle and could be more pronounced in women with PMS. While IRT effectively reduced nightmare severity overall, its specific impact on nightmares in women with PMS requires further research in larger studies.
- 28 February 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (3)
Open AccessNightmares Fluctuate Across the Menstrual Cycle and May be More Pronounced in Women With Premenstrual Syndrome
Introduction: Premenstrual syndrome (PMS) affects nearly half of women worldwide and is associated with sleep disturbances, though the specific relationship between PMS and nightmares remains underexplored. Clinical observations suggest a potential link, leading this study to investigate whether women with PMS experience more frequent or intense nightmares compared to those without PMS.Methods: We conducted a prospective case series of seven women experiencing nightmares, all of whom participated in weekly imagery rehearsal therapy (IRT) over 1‐month. Each participant completed the daily record of severity of problems (DRSP) to assess PMS symptoms and kept daily dream diaries throughout one menstrual cycle, tracking nightmare frequency, intensity, and emotional valence. The nightmare severity index (NSI) was administered at the beginning and end of the study. Descriptive analysis was used for the dream metrics, and the Wilcoxon signed‐rank test was employed to assess changes in NSI scores.Results: Women with PMS exhibited an increase in nightmare frequency during the premenstrual phase, but no formal statistical comparisons were made between PMS and non‐PMS groups regarding dream frequency or intensity. A significant reduction in NSI scores (p = 0.03) was observed across the entire sample, though this effect was not significant in the PMS subgroup.Conclusions: This case series is the first, to our knowledge, to provide detailed longitudinal data indicating that nightmare frequency may fluctuate across the menstrual cycle and could be more pronounced in women with PMS. While IRT effectively reduced nightmare severity overall, its specific impact on nightmares in women with PMS requires further research in larger studies.
- Open Access
- 28 February 2025
- Vol. 15 (3)
Nightmares Fluctuate Across the Menstrual Cycle and May be More Pronounced in Women With Premenstrual Syndrome
Premenstrual syndrome (PMS) affects nearly half of women worldwide and is associated with sleep disturbances, though the specific relationship between PMS and nightmares remains underexplored. Clinical observations suggest a potential link, leading this study to investigate whether women with PMS experience more frequent or intense nightmares compared to those without PMS. We conducted a prospective case series of seven women experiencing nightmares, all of whom participated in weekly imagery rehearsal therapy (IRT) over 1‐month. Each participant completed the daily record of severity of problems (DRSP) to assess PMS symptoms and kept daily dream diaries throughout one menstrual cycle, tracking nightmare frequency, intensity, and emotional valence. The nightmare severity index (NSI) was administered at the beginning and end of the study. Descriptive analysis was used for the dream metrics, and the Wilcoxon signed‐rank test was employed to assess changes in NSI scores. Women with PMS exhibited an increase in nightmare frequency during the premenstrual phase, but no formal statistical comparisons were made between PMS and non‐PMS groups regarding dream frequency or intensity. A significant reduction in NSI scores (p = 0.03) was observed across the entire sample, though this effect was not significant in the PMS subgroup. This case series is the first, to our knowledge, to provide detailed longitudinal data indicating that nightmare frequency may fluctuate across the menstrual cycle and could be more pronounced in women with PMS. While IRT effectively reduced nightmare severity overall, its specific impact on nightmares in women with PMS requires further research in larger studies.
- 28 February 2025
- Vol. 15 (3)
Open AccessNightmares Fluctuate Across the Menstrual Cycle and May be More Pronounced in Women With Premenstrual Syndrome
Premenstrual syndrome (PMS) affects nearly half of women worldwide and is associated with sleep disturbances, though the specific relationship between PMS and nightmares remains underexplored. Clinical observations suggest a potential link, leading this study to investigate whether women with PMS experience more frequent or intense nightmares compared to those without PMS. We conducted a prospective case series of seven women experiencing nightmares, all of whom participated in weekly imagery rehearsal therapy (IRT) over 1‐month. Each participant completed the daily record of severity of problems (DRSP) to assess PMS symptoms and kept daily dream diaries throughout one menstrual cycle, tracking nightmare frequency, intensity, and emotional valence. The nightmare severity index (NSI) was administered at the beginning and end of the study. Descriptive analysis was used for the dream metrics, and the Wilcoxon signed‐rank test was employed to assess changes in NSI scores. Women with PMS exhibited an increase in nightmare frequency during the premenstrual phase, but no formal statistical comparisons were made between PMS and non‐PMS groups regarding dream frequency or intensity. A significant reduction in NSI scores (p = 0.03) was observed across the entire sample, though this effect was not significant in the PMS subgroup. This case series is the first, to our knowledge, to provide detailed longitudinal data indicating that nightmare frequency may fluctuate across the menstrual cycle and could be more pronounced in women with PMS. While IRT effectively reduced nightmare severity overall, its specific impact on nightmares in women with PMS requires further research in larger studies.
- Open Access
- 28 February 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e58262
A Digital Program for Daily Life Management With Endometriosis: Pilot Cohort Study on Symptoms and Quality of Life Among Participants
Background: After experiencing symptoms for an average of 7 years before diagnosis, patients with endometriosis are usually left with more questions than answers about managing their symptoms in the absence of a cure. To help women with endometriosis after their diagnosis, we developed a digital program combining user research, evidence-based medicine, and clinical expertise. Structured around cognitive behavioral therapy and the quality of life metrics from the Endometriosis Health Profile score, the program was designed to guide participants for 3 months. Objective: This cohort study was designed to measure the impact of a digital health program on the symptoms and quality of life levels of women with endometriosis. Methods: In total, 63% (92/146) of the participants were included in the pilot study, recruited either free of charge through employer health insurance or via individual direct access. A control group of 404 women with endometriosis who did not follow the program, recruited through social media and mailing campaigns, was sampled (n=149, 36.9%) according to initial pain levels to ensure a similar pain profile to participants. Questionnaires assessing quality of life and symptom levels were emailed to both groups at baseline and 3 months. Descriptive statistics and statistical tests were used to analyze intragroup and intergroup differences, with Cohen d measuring effect sizes for significant results. Results: Over 3 months, participants showed substantial improvements in global symptom burden, general pain level, anxiety, depression, dysmenorrhea, dysuria, chronic fatigue, neuropathic pain, and endo belly. These improvements were significantly different from the control group for global symptom burden (participants: mean –0.7, SD 1.6; controls: mean –0.3, SD 1.3; P=.048; small effect size), anxiety (participants: mean –1.1, SD 2.8; controls: mean 0.2, SD 2.5; P<.001; medium effect size), depression (participants: mean –0.9, SD 2.5; controls: mean 0.0, SD 3.1; P=.04; small effect size), neuropathic pain (participants: mean –1.0, SD 2.7; controls: mean –0.1, SD 2.6; P=.004; small effect size), and endo belly (participants: mean –0.9, SD 2.5; controls: mean –0.3, SD 2.4; P=.03; small effect size). Participants’ quality of life improved between baseline and 3 months and significantly differed from that of the control group for the core part of the Endometriosis Health Profile-5 (participants: mean –5.9, SD 21.0; controls: mean 1.0, SD 14.8; P=.03; small effect size) and the EQ-5D (participants: mean 0.1, SD 0.1; controls: mean –0.0, SD 0.1; P=.001; medium effect size). Perceived knowledge of endometriosis was significantly greater at 3 months among participants compared to the control group (P<.001). Conclusions: This study’s results suggest that a digital health program providing medical and scientific information about endometriosis and multidisciplinary self-management tools may be useful to reduce global symptom burden, anxiety, depression, neuropathic pain, and endo belly while improving knowledge on endometriosis and quality of life among participants.
- 28 February 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e58262
Open AccessA Digital Program for Daily Life Management With Endometriosis: Pilot Cohort Study on Symptoms and Quality of Life Among Participants
Background: After experiencing symptoms for an average of 7 years before diagnosis, patients with endometriosis are usually left with more questions than answers about managing their symptoms in the absence of a cure. To help women with endometriosis after their diagnosis, we developed a digital program combining user research, evidence-based medicine, and clinical expertise. Structured around cognitive behavioral therapy and the quality of life metrics from the Endometriosis Health Profile score, the program was designed to guide participants for 3 months. Objective: This cohort study was designed to measure the impact of a digital health program on the symptoms and quality of life levels of women with endometriosis. Methods: In total, 63% (92/146) of the participants were included in the pilot study, recruited either free of charge through employer health insurance or via individual direct access. A control group of 404 women with endometriosis who did not follow the program, recruited through social media and mailing campaigns, was sampled (n=149, 36.9%) according to initial pain levels to ensure a similar pain profile to participants. Questionnaires assessing quality of life and symptom levels were emailed to both groups at baseline and 3 months. Descriptive statistics and statistical tests were used to analyze intragroup and intergroup differences, with Cohen d measuring effect sizes for significant results. Results: Over 3 months, participants showed substantial improvements in global symptom burden, general pain level, anxiety, depression, dysmenorrhea, dysuria, chronic fatigue, neuropathic pain, and endo belly. These improvements were significantly different from the control group for global symptom burden (participants: mean –0.7, SD 1.6; controls: mean –0.3, SD 1.3; P=.048; small effect size), anxiety (participants: mean –1.1, SD 2.8; controls: mean 0.2, SD 2.5; P<.001; medium effect size), depression (participants: mean –0.9, SD 2.5; controls: mean 0.0, SD 3.1; P=.04; small effect size), neuropathic pain (participants: mean –1.0, SD 2.7; controls: mean –0.1, SD 2.6; P=.004; small effect size), and endo belly (participants: mean –0.9, SD 2.5; controls: mean –0.3, SD 2.4; P=.03; small effect size). Participants’ quality of life improved between baseline and 3 months and significantly differed from that of the control group for the core part of the Endometriosis Health Profile-5 (participants: mean –5.9, SD 21.0; controls: mean 1.0, SD 14.8; P=.03; small effect size) and the EQ-5D (participants: mean 0.1, SD 0.1; controls: mean –0.0, SD 0.1; P=.001; medium effect size). Perceived knowledge of endometriosis was significantly greater at 3 months among participants compared to the control group (P<.001). Conclusions: This study’s results suggest that a digital health program providing medical and scientific information about endometriosis and multidisciplinary self-management tools may be useful to reduce global symptom burden, anxiety, depression, neuropathic pain, and endo belly while improving knowledge on endometriosis and quality of life among participants.
- Open Access
- 17 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Innovative Digital Cognitive Behavioral Treatment for Insomnia Disorder in Adults (dCBT-i): Framework Development (Preprint)
BACKGROUND Chronic insomnia, or insomnia disorder, is a major health issue with a prevalence of up to 15%. The recommended first-line treatment is cognitive behavioral therapy for insomnia (CBT-i), which, unfortunately, remains insufficiently accessible. Digitalization has the potential to reduce health care access inequalities by offering more flexible and accessible care options. Digital CBT-i (dCBT-i) has been shown to be as effective as in-person CBT-i, highlighting its potential for broader implementation. OBJECTIVE This study aimed to develop an evidence-based dCBT-i program grounded in theoretical and clinical knowledge, designed for efficient integration into health care systems, and to establish it as the first prescribed digital treatment in France. METHODS The program was constructed based on validated CBT-i theory and practice, incorporating the latest scientific data on CBT for insomnia. It was designed as a robust multicomponent therapy, integrating an initial standardized assessment and daily intelligent adaptation to enable digital phenotyping and provide personalized treatment. RESULTS We developed an innovative digital solution that combines scientific rigor with practical application. The program includes a standardized initial evaluation and dynamic personalization through intelligent algorithms. These features allow for the adaptation of therapy based on patient progress and needs, ensuring individualized care. CONCLUSIONS The development of this dCBT-i program represents a significant milestone in digital health care, offering a scalable solution to the accessibility challenges of traditional CBT-i. Future steps involve conducting clinical studies to further evaluate its effectiveness and optimize its implementation within health care systems.
- 17 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessInnovative Digital Cognitive Behavioral Treatment for Insomnia Disorder in Adults (dCBT-i): Framework Development (Preprint)
BACKGROUND Chronic insomnia, or insomnia disorder, is a major health issue with a prevalence of up to 15%. The recommended first-line treatment is cognitive behavioral therapy for insomnia (CBT-i), which, unfortunately, remains insufficiently accessible. Digitalization has the potential to reduce health care access inequalities by offering more flexible and accessible care options. Digital CBT-i (dCBT-i) has been shown to be as effective as in-person CBT-i, highlighting its potential for broader implementation. OBJECTIVE This study aimed to develop an evidence-based dCBT-i program grounded in theoretical and clinical knowledge, designed for efficient integration into health care systems, and to establish it as the first prescribed digital treatment in France. METHODS The program was constructed based on validated CBT-i theory and practice, incorporating the latest scientific data on CBT for insomnia. It was designed as a robust multicomponent therapy, integrating an initial standardized assessment and daily intelligent adaptation to enable digital phenotyping and provide personalized treatment. RESULTS We developed an innovative digital solution that combines scientific rigor with practical application. The program includes a standardized initial evaluation and dynamic personalization through intelligent algorithms. These features allow for the adaptation of therapy based on patient progress and needs, ensuring individualized care. CONCLUSIONS The development of this dCBT-i program represents a significant milestone in digital health care, offering a scalable solution to the accessibility challenges of traditional CBT-i. Future steps involve conducting clinical studies to further evaluate its effectiveness and optimize its implementation within health care systems.